跳至主要内容
临床试验/NCT02221154
NCT02221154终止4 期

Use of Myo-inositol as Adjuvant Therapy in Patients With Polycystic Ovary Syndrome (PCOS) in Vitro Fertilization (IVF)

Centre Hospitalier Departemental Vendee8 个研究点 分布在 1 个国家目标入组 49 人开始时间: 2014年11月最近更新:
适应症

试验速览

阶段
4 期
状态
终止
入组人数
49
试验地点
8
主要终点
Incidence of OHSS in each group, graded mild, moderate or severe based on the recommendations

研究概览

简要总结

The original mechanism of action of myo-inositol and preliminary results available in the literature on its use in IVF suggest its value as adjuvant gonadotropin therapy to reduce the risk of OHSS in PCOS patients.

The aim of the study is to demonstrate that administration of myo-inositol decreases the incidence of ovarian hyperstimulation syndrome (OHSS) in high-risk infertile with PCOS supported in IVF patients.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 38 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Patients PCOS (Rotterdam ESHRE / ASRM criteria)
  • Combination of at least two of the following three criteria:
  • Cycle disorder
  • Clinical hyperandrogenism and / or biological
  • Account antral follicles> 24
  • Age ≤ 18 ≤ 38 years
  • BMI <35 kg / m²
  • Able to understand the protocol and signed informed consent

排除标准

  • Patients not having the Rotterdam criteria
  • Patients> 38 years and / or BMI> 35 kg / m²
  • Woman enjoying a measure of legal protection
  • Hypersensitivity to any component of the Inofolic (myo-inositol, soy, folic acid, glycerol, gelatin, coloring E171)
  • Participation in another interventional biomedical research with treatment administered may disrupt ovarian stimulation

结局指标

主要结局

Incidence of OHSS in each group, graded mild, moderate or severe based on the recommendations

时间窗: 3 month

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (8)

Loading locations...

相似试验